When valproic acid, ethosuximide, or levetiracetam fails in CSWS: what comes next
Clinical scenario
Epileptic encephalopathy with continuous spike-and-wave during sleep (CSWS) is characterised by sustained epileptiform discharges during non-REM sleep that drive progressive deterioration in neurocognitive function. When a first-line anti-seizure medication (ASM) course does not produce an adequate clinical or electroencephalographic response, a structured next-line protocol guides subsequent management.
Previous line — response targets not reached
This protocol applies after treatment with valproic acid, ethosuximide, or levetiracetam has failed to achieve the defined response thresholds:
- Clinical improvement in neurocognitive function, seizure burden, or the EEG
- At least a 50% reduction in the sleep spike wave index (SWI) on post-treatment EEG
Next-line approach (partial overview)
The next step involves a specialised dietary intervention that has been studied in CSWS patients. Eligibility criteria, initiation details, and monitoring requirements are set out in the full structured protocol.
Response targets
- Clinical response: measurable improvement in neurocognitive function, seizures, or the EEG
- SWI response: ≥50% reduction in sleep spike wave index comparing post- and pre-treatment EEGs
References
- DOI: 10.1016/j.jpeds.2021.01.032
- In addition, the ketogenic diet has been studied in a number of CSWS patients with varying degrees of success.
- The clinical response was defined as clinical improvement in neurocognitive function, seizures, or the EEG after therapy as judged and documented in the medical record by the treating neurologist.
- The SWI response was defined by a 50% reduction in the sleep SWI when comparing the post- and pre-treatment EEGs.
View source ↗